This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
ELISA/assay
product name :
CD47: SIRP alpha [Biotinylated] Inhibitor Screening ELISA Assay Pair
catalog :
EP-102
quantity :
480 tests, 96 tests
price :
2150 USD, 600 USD
product information
company name :
ACROBiosystems
product type :
Kits
catalog :
EP-102
product name :
CD47: SIRP alpha [Biotinylated] Inhibitor Screening ELISA Assay Pair
quantity :
480 tests, 96 tests
price :
2150 USD, 600 USD
quantity & price :
$600/96tests,$2150/480tests
target :
CD47
host species :
Human
Research :
For Research Use Only
Formulation :
Please contact us for detailed information.
Reconstitution :
See Certificate of Analysis for details of reconstitution instruction and specific concentration.
Storage :
Upon receipt, please store all items at -70℃.
After reconstitution, the stock solution should be kept at -70℃. It is recommended not to freeze thaw more than 3 times. This product is stable after storage at:
Room temperature (RT) for 1 month in lyophilized state;
-20℃ for 1 year in lyophilized state;
-70℃ for 6 months under sterile conditions after reconstitution.
Background :
Immune checkpoint pathway is a focal point of today’s cancer research. CD47 is one of the best characterized checkpoint proteins. CD47 binding to SIRP alpha aids in tumor evasion of the immune system. Therefore, the pharmaceutical inhibition of CD47 has been considered a promising strategy by many oncologists.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments